Skip to content
lifestyle.infotechinc.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Senti Biosciences, Inc.
Senti Bio Announces Reverse Stock Split
November 17, 2026
Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform
July 15, 2026
Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
February 13, 2026